XXXIII Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia

Ponencias 91 46. Zhang H, Lowenberg EC, Crosby JR, MacLeod AR, Zhao C, et al. Inhibition of the intrinsic coagulation pathway factor XI by anti- sense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood 2010;116:4684-92. 47. Younis HS, Crosby JR, Huh JI, Lee HS, Rime S, et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood 2012;119:2401-8. 48. Crosby JR, Marzec U, Revenko AS, Zhao C, Gao D, et al. Anti- thrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol 2013;33:1670-8. 49. Yau JW, Liao P, Fredenburgh JC, Stafford AR, Revenkok AS, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 2014;123:2102-7. 50. Zhong C, Hang L, Hen L, Deng L, I L. Coagulation factor XI vac- cination: an alternative strategy to prevent thrombosis. J Thromb Haemost 2017;15:122-30. 51. Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015;372:232-40. 52. Takamizawa Y, Araki M, Yoshida N, Yoshioka T, Miura K. A case of a severe factor XI deficiency in patient undergoing hemodialysis without the use of heparin. Blood Coagul Fibrinolysis 2014;25:898-9. 53. Woodruff RS, XuY, Layzer J, Wu W, Ogletree ML, et al. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost 2013;11:1364-73. 54. David T, KimYC, Ely LK, Rondon I, Gao H, et al. Factor XIa-specif- ic IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis. Sci Transl Med 2016;8:353ra112. 55. Matafonov A, Leung PY, Gailani AE, Grach SL, Puy C, et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 2014;123:1739-46. 56. Tucker EI, Marzec UM, White TC, Hurst S, Rugonyi S, et al. Preven- tion of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009;113:936-44. 57. Al-Horani RA, Ponnusamy P, Mehta AY, Gailani D, Desai UR. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J Med Chem 2013;56:867-78. 58. Al-Horani RA, Desai UR. Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopy- ranosides. J Med Chem 2014;57:4805-18. 59. Quan ML, Wong PC, Wang C, Woerner F, Smallheer JM, et al. Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors. J Med Chem 2014;57:955-69. 60. Wong PC, Crain EJ, Watson CA, Schumacher WA. A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis 2011;32:129-37. 61. Zhu S, Travers RJ, Morrissey JH, Diamond SL. FXIa and plate- let polyphosphate as therapeutic targets during human blood clotting on collagen/tissue factor surfaces under flow. Blood 2015;126:1494-502. 62. Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathy JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014;124:3183-90. 63. Jain S, Pitoc GA, Holl EK, Zhang Y, Borst L, et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci U S A 2012;109:12938-43.